Nachrichten zur SELLAS Life Sciences Group Aktie

SELLAS Life Sciences Group (SLS) im Pivotal-Point-Check: Aussicht auf bahnbrechende Überlebensdaten bei AML sorgt für 18 % Kursfeuerwerk!

Fortgeschrittene Krebsstudie: Das wichtigste Medikament Galinpepimut-S (GPS) steht unmittelbar vor dem entscheidenden Meilenstein der Phase 3. Zuversicht der Führungsebene:…

SELLAS Life Sciences: Diese Phase-3-Daten könnten alles verändern

SELLAS Life Sciences Group ist ein US-amerikanisches Biotechnologieunternehmen im Spätstadium der klinischen Entwicklung, das sich auf neuartige Krebstherapien spezialisiert hat.…

All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy

SELLAS Life Sciences Group, Inc. (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the…

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the…

SELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)

SELLAS Life Sciences Group (SLS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys…

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the…

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the…

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

…

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the…

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the…

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the…

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the…

dpa-AFX ProFeed